AI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal Cancer
Development and Validation of an Artificial Intelligence Prediction Model and a Survival Risk Stratification for Lung Metastasis in Colorectal Cancer From Highly Imbalanced Data
1 other identifier
observational
2,779
0 countries
N/A
Brief Summary
Background: To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients. Method: The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. The optimization model with best performance was compared to the clinical predictor. In addition, stratified LM patients by risk score were utilized for survival analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedFirst Submitted
Initial submission to the registry
April 5, 2023
CompletedFirst Posted
Study publicly available on registry
April 18, 2023
CompletedApril 18, 2023
April 1, 2023
5 years
April 5, 2023
April 5, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
lung metastasis
diagnosed with lung metastasis
through study completion, an average of 3 month
Study Arms (2)
validation set 1
The validation set 1 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.
validation set 2
The validation set 2 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Second Affiliated Hospital of Harbin Medical University.
Interventions
The location of the patient's treatment
Eligibility Criteria
patients with pathologic confirmation of a primary CRC diagnosis
You may qualify if:
- patients with pathologic confirmation of a primary CRC diagnosis
You may not qualify if:
- (1) patients with multiple primary cancers or other malignancies; (2) patients identified via autopsy or death certificate; and (3) patients with uncertain clinical data values
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College
Study Record Dates
First Submitted
April 5, 2023
First Posted
April 18, 2023
Study Start
January 1, 2016
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
April 18, 2023
Record last verified: 2023-04